Cat. No.: HY-B0118A

Vecuronium bromide

Name: Vecuronium bromide
Brand: MedChemExpress
SKU: HY-B0118A
Price: 115.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: ORG NC 45)

고객리뷰

Based on 1 Customer Validation

Vecuronium (ORG NC 45) bromide is a non-depolarizing neuromuscular blocking agent that also acts as a nicotinic acetylcholine receptor (nAChR) inhibitor, a muscle relaxant, and can be used for pre-surgical anesthesia.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity : 99.93%
CAS No.: 50700-72-6
화학식: C₃₄H₅₇BrN₂O₄
분자량:637.73

보관:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Vecuronium bromide Chemical Structure

CAS No.: 50700-72-6

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	1.9 μM Compound: vecuronium bromide	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	25.2 μM Compound: vecuronium bromide	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	3.5 μM Compound: vecuronium bromide	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]

In Vitro

Vecuronium bromide (0-100 μM, 15 min) inhibits [³H] norepinephrine (NE) uptake to 65% at 100 μM in adrenal medullary cells^[1].
Vecuronium bromide (0-15 μM,72 hours) inhibits cancer cell proliferation and migration in a concentration-dependent manner^[2].
Vecuronium bromide (0-15 μM,72 hours) can significantly reduce cell viability by combining with cisplatin^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

Lung cancer cell line (A549)
Concentration:

0-15 μM
Incubation Time:

72 hours
Result:

Inhibited cell proliferation at concentrations ranging from 5.0 μM to 15 μM.

Cell Cytotoxicity Assay^[2]

Cell Line:

Lung cancer cell line (A549)
Concentration:

0-15 μM
Incubation Time:

72 hours
Result:

Resulted in a decrease in cell viability from 10 μM to 15 Μm by combining with cisplatin.

In Vivo

Vecuronium bromide (Intravenous injection, 0-5 μM, every 30 min, 2 hours) attenuates the response of carotid sinus nerve activity (CSNA) to hypoxia in a dose-dependent manner and inhibits the neural response of the carotid body to acetylcholine (ACh) in Wister rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wister rats weighing 250-350 g^[3]
Dosage:

0-5 μM
Administration:

Intravenous injection; every 30 min; 2 hours
Result:

Significantly diminished CSNA response to hypoxia at the concentration of 5 μM and reduced carotid sinus nerve response to ACh at 0.5 μM.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991			2011-05	PHASE1

Chemical Information

CAS No. 50700-72-6
Appearance Solid
분자량 637.73
화학식 C₃₄H₅₇BrN₂O₄
Color White to off-white
SMILES

C[C@@]1([C@H]2OC(C)=O)[C@](C[C@@H]2[N+]3(CCCCC3)C)([H])[C@@](CC[C@]4([H])[C@@]5(C[C@H](N6CCCCC6)[C@@H](OC(C)=O)C4)C)([H])[C@]5([H])CC1.[Br-]
Synonyms

ORG NC 45
선적

Room temperature in continental US; may vary elsewhere.
보관

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

용액&용해도

In Vitro:

H₂O : ≥ 100 mg/mL (156.81 mM)

DMSO : 83.33 mg/mL (130.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5681 mL

7.8403 mL

15.6806 mL

5 mM

0.3136 mL

1.5681 mL

3.1361 mL

10 mM

0.1568 mL

0.7840 mL

1.5681 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. K Uryu, et al. Inhibition by neuromuscular blocking drugs of norepinephrine transporter in cultured bovine adrenal medullary cells. Anesth Analg. 2000 Sep;91(3):546-51. [Content Brief]

[2]. Iddrisu BabaYabasin, et al. Anticancer effects of vecuronium bromide and cisatracurium besylate on lung cancer cells (A549), in vitro. Biomedicine & Aging Pathology,Volume 4, Issue 4,

[3]. Ayuko Igarashi,et al. Vecuronium directly inhibits hypoxic neurotransmission of the rat carotid body. Anesth Analg. 2002 Jan;94(1):117-22, table of contents. [Content Brief]

[4]. Meretoja, O.A., Vecuronium infusion requirements in pediatric patients during fentanyl-N2O-O2 anesthesia. Anesth Analg, 1989. 68(1): p. 20-4. [Content Brief]

[5]. Agoston, S., et al., The neuromuscular blocking action of ORG NC 45, a new pancuronium derivative, in anaesthetized patients. A pilot study. Br J Anaesth, 1980. 52 Suppl 1: p. 53S-59S. [Content Brief]

[6]. Shingu, K., et al., [Neuromuscular blocking effects of Org 9426 (rocuronium bromide); a comparative study with vecuronium bromide in Japanese patients]. Masui, 2006. 55(9): p. 1140-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	1.5681 mL	7.8403 mL	15.6806 mL	39.2015 mL
	5 mM	0.3136 mL	1.5681 mL	3.1361 mL	7.8403 mL
	10 mM	0.1568 mL	0.7840 mL	1.5681 mL	3.9202 mL
	15 mM	0.1045 mL	0.5227 mL	1.0454 mL	2.6134 mL
	20 mM	0.0784 mL	0.3920 mL	0.7840 mL	1.9601 mL
	25 mM	0.0627 mL	0.3136 mL	0.6272 mL	1.5681 mL
	30 mM	0.0523 mL	0.2613 mL	0.5227 mL	1.3067 mL
	40 mM	0.0392 mL	0.1960 mL	0.3920 mL	0.9800 mL
	50 mM	0.0314 mL	0.1568 mL	0.3136 mL	0.7840 mL
	60 mM	0.0261 mL	0.1307 mL	0.2613 mL	0.6534 mL
	80 mM	0.0196 mL	0.0980 mL	0.1960 mL	0.4900 mL
	100 mM	0.0157 mL	0.0784 mL	0.1568 mL	0.3920 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Vecuronium bromide